Revenue Growth YoY (Last 12 Months): 23andMe Inc (ME)

The high margins of 23andMe Holding Co. (ME) are based on the robotization of molecular tests, which eliminates manual labor. The year-over-year sales growth trajectory for the TTM clearly demonstrates sales dynamics, where the indicator remains at -19.10. While large-scale automation of DNA analysis accelerates the delivery of results, cybersecurity issues and data monetization challenges are forcing the brand to transform into a full-fledged clinic.
Summary analytical data breakdowns for 23andMe Inc (ME)

This indicator captures the percentage change in revenue over the last twelve months relative to the same period last year, allowing for the removal of seasonality to identify the true scaling vector of the business. By analyzing the TTM revenue growth rates year-over-year, an investor assesses the effectiveness of 23andMe Holding Co. (ME) transitioning from consumer software to the monetization of its R&D platform in the field of targeted therapy development.